ArticleBJS open2026
Comparison of transoral and bilateral axillo-breast approach endoscopic thyroidectomy: multicentre study.
Article in BJS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundRemote-access thyroidectomy techniques such as the transoral endoscopic thyroidectomy vestibular approach (TOETVA) and bilateral axillo-breast approach (BABA) offer cosmetic advantages, yet multicentre evidence comparing perioperative safety, operative efficiency, and histopathological integrity is limited.
methodsThis retrospective multicentre cohort study included consecutive adult patients who underwent TOETVA or BABA at four tertiary referral centres between 1 January 2020 and 31 December 2022. Surgeons had surpassed the learning curve. Propensity score matching (1 : 1) was performed based on demographic and clinical variables. Patients with < 12 months follow-up were excluded. Data on operative time (total and phase-specific), postoperative pain, complications, specimen integrity (fragmentation and capsule status), length of hospital stay, reoperations, and mid-term outcome measures, including recurrence, were collected.
resultsFor 507 eligible patients (TOETVA, 216; BABA, 291), matching achieved balanced baseline characteristics. TOETVA had longer operative time than BABA (125.6 versus 97.7 minutes; P < 0.001), with faster flap creation but slower thyroidectomy. Complication rates were similar for TOETVA and BABA, including vocal cord palsy (1.1% versus 2.8%, respectively) and hypoparathyroidism (2.2% versus 3.3%, respectively). TOETVA had higher rates of specimen disruption (12.8% versus 6.1%; P = 0.031), whereas tumour capsule integrity was comparable. Bilateral thyroidectomy independently prolonged operative time in both groups; tumour size and male sex also increased operative time in BABA. Mid-term recurrence was uncommon, although recurrence after BABA more often required open or chest wall incisions, whereas recurrence after TOETVA was managed through a limited cervical approach.
conclusionTOETVA and BABA are safe and effective remote-access thyroidectomy options, each with distinct technical considerations. TOETVA offers a scarless mid-line corridor with less postoperative discomfort but carries a higher risk of specimen disruption, whereas BABA provides broader exposure and shorter thyroidectomy time but is more affected by anatomical and tumour factors. These findings support evidence-based surgical planning and individualized patient counselling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.